Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus: Results From the CANVAS Program

Circulation

Volumn 139, Issue 22, 2019, Pages 2591-2593

  Figtree, Gemma A ^a,b   Rådholm, Karin ^b,c   Barrett, Terrance D ^d   Perkovic, Vlado ^b   Mahaffey, Kenneth W ^e   De Zeeuw, Dick ^f   Fulcher, Greg ^a   Matthews, David R ^g   Shaw, Wayne ^d   Neal, Bruce ^b,h  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c LINKÖPING UNIVERSITY   (Sweden)

^d JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^g UNIVERSITY OF OXFORD   (United Kingdom)

^h IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

canagliflozin; heart failure; randomized trial; SGLT2 inhibitor; type 2 diabetes mellitus

Indexed keywords

CANAGLIFLOZIN;

ADULT; CARDIOVASCULAR RISK; CLINICAL OUTCOME; CONTROLLED STUDY; FEMALE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART FAILURE WITH REDUCED EJECTION FRACTION; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK REDUCTION; ADVERSE EVENT; CLINICAL TRIAL; COMPARATIVE STUDY; CONVALESCENCE; DRUG EFFECT; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; MORTALITY; MULTICENTER STUDY; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME;

ADULT; CANAGLIFLOZIN; DIABETES MELLITUS, TYPE 2; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; RECOVERY OF FUNCTION; RISK FACTORS; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; STROKE VOLUME; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 85063954068     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.119.040057     Document Type: Letter

References (4)

1. Cavender MA, Steg PG, Smith SC Jr, Eagle K, Ohman EM, Goto S, Kuder J, Im K, Wilson PW, Bhatt DL; on behalf of the REACH Registry Investigators. Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death: Outcomes at 4 years from the Reduction of Atherothrombosis for Continued Health (REACH) Registry. Circulation. 2015;132: 923-931. doi: 10.1161/CIRCULATIONAHA.114.014796
2. Radholm K, Figtree G, Perkovic V, Solomon SD, Mahaffey KW, de Zeeuw D, Fulcher G, Barrett TD, Shaw W, Desai M, Matthews DR, Neal B. Canagliflozin and heart failure in type 2 diabetes mellitus: Results from the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). Circulation. 2018;138: 458-468. doi: 10.1161/CIRCULATIONAHA.118.034222
3. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews D; on behalf of the CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377: 644-657. doi: 10.1056/NEJMoa1611925
4. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; for the EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373: 2117-2128. doi: 10.1056/NEJMoa1504720